Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05692570 · ClinicalTrials.gov registry record · Phase 1

A Study of PBI-200 With Ritonavir or Cobicistat in Healthy Volunteers

A Phase 1 study, sponsored by Pyramid Biosciences.

Completed
Registry status
Phase 1
Development phase
21
Enrollment target

NCT05692570: Completed Phase 1 study, sponsored by Pyramid Biosciences.

NCT05692570 is a Phase 1 study that has completed, run by Pyramid Biosciences. The registered enrollment target is 21 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (65% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05692570, a Phase 1 study, has completed, sponsored by Pyramid Biosciences.

COMPLETED
Registry status
Phase 1
Development phase
21 participants
Enrollment target

Study Summary

This is a drug-drug interaction study in volunteers to evaluate the effect of ritonavir or cobicistat on the pharmacokinetics (PK) of PBI-200.

Primary Outcome

Maximum (peak) plasma drug concentration

Interventions

  • DRUG PBI-200 Tablet
  • DRUG Ritonavir Oral Tablet
  • DRUG Cobicistat Oral Tablet

Trial Details

FieldValue
Enrollment Target 21 participants
Start Date 2022-09-09
Est. Completion 2022-11-12
Phase Phase 1
Pyramid Biosciences

7 total trials

What the finished NCT05692570 record still lists

NCT05692570 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (65% lower).

The record links to 0 conditions, and to 3 interventions - of which PBI-200 Tablet is the first listed.

NCT05692570 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT05692570 about?

NCT05692570 is a clinical study titled "A Study of PBI-200 With Ritonavir or Cobicistat in Healthy Volunteers". This is a drug-drug interaction study in volunteers to evaluate the effect of ritonavir or cobicistat on the pharmacokinetics (PK) of PBI-200.

What is the current status of trial NCT05692570?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2022-09-09. Estimated completion is 2022-11-12.

What interventions are being tested in trial NCT05692570?

The interventions under investigation include: PBI-200 Tablet (DRUG), Ritonavir Oral Tablet (DRUG), Cobicistat Oral Tablet (DRUG).

Who is sponsoring clinical trial NCT05692570?

This trial is sponsored by Pyramid Biosciences, which has 7 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT05692570's enrollment target sits among peer trials

21 1615th of 2000 higher than 372 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02447874 · 21 participants · Phase 1

    Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease

  • NCT03826992 · 21 participants · Phase 1

    Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia

  • NCT04107077 · 21 participants · Phase 2

    Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer

  • NCT04158635 · 21 participants · Phase 1

    Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05692570, the US trial registry maintained by the National Library of Medicine. NCT05692570 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.